Company Overview and News

11
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

10h zacks
Shares of CTI BioPharma Corp. (CTIC - Free Report) plunged 43.4% after the company announced the outcome of a Type B meeting with the FDA, discussing a regulatory pathway for its lead pipeline candidate pacritinib. Per the FDA’s request, the company will have to conduct a phase III study on patients with myelofibrosis.
BLRX INCY CTIC CTI ACRX

9
ACRX / AcelRx Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-07-13 sec.gov
acrx20180712_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ACRX

9
ACRX / AcelRx Pharmaceuticals, Inc. FORM 424B5 (Prospectus)

2018-07-13 sec.gov
acrx20180627_424b5.htm Filed pursuant to Rule 424(b)(5) Registration No. 333-218506
ACRX

9
ACRX / AcelRx Pharmaceuticals, Inc. FORM 424B5 (Prospectus)

2018-07-11 sec.gov
acrx20180627_424b5.htm Filed pursuant to Rule 424(b)(5) Registration No. 333-218506
ACRX

9
ACRX / AcelRx Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-07-11 sec.gov
acrx20180702b_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ACRX

22
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

2018-07-11 zacks
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) reported encouraging preliminary sales figure for its lead drug, Exparel.
CLGN JNJ PCRX ACRX CQPTY

11
VIVUS' PAH Candidate Data Positive in Early Stage Study

2018-07-11 zacks
VIVUS, Inc. (VVUS - Free Report) announced positive preliminary data from a phase I study evaluating VI-0106, a proprietary soft capsule formulation of tacrolimus, for the treatment of pulmonary arterial hypertension (“PAH”).
VVUS BLRX CLGN ACRX CQPTY

9
Aclaris' Alopecia Candidate Gets Fast Track Designation

2018-07-10 zacks
Aclaris Therapeutics, Inc. (ACRS - Free Report) shares increased 1.5% on Jul 9 after the company announced that its Janus kinase (“JAK”) inhibitor, ATI-502, has been granted a fast track designation by the FDA.
ACRS BLRX CLGN ACRX CQPTY

83
ACRX / AcelRx Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-07-02 sec.gov
acrx20180702b_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ACRX

80
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

2018-06-22 zacks
Shire plc (SHPG - Free Report) announced that the FDA has approved the label expansion of its hereditary angioedema (HAE) drug, Cinryze, to use in children aged six years and above.
BLRX CTLT ACRX

79
AcelRx Sparks Investor Interest As It Gears Up For Another Shot With Dsuvia

2018-06-17 seekingalpha
In October 2017, ACRX received a CRL for its pain drug Dsuvia; the FDA cited concerns with maximum dosage and the directions for use printed on the proposed packaging.
ACRX PDLI

128
Top Ranked Momentum Stocks to Buy for June 15th

2018-06-15 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 15th:
APC SPG.PRJ SPG ACRX ABMD AEUA

76
ACRX / AcelRx Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-15 sec.gov
acrx20180614_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ACRX

179
An Integrated BioSci Rounds Report: Madrigal Continued Its Rally While Improving FDA Policy To Benefit Nektar

2018-06-07 seekingalpha
The overall bioscience market traded higher due to increasing investor confidence. Many equities under our coverage continued to post further gains.
ENTA NKTR MDGL GILD SNTA CNAT ICPT IBB ACRX XBI

102
Top Ranked Momentum Stocks to Buy for June 5th

2018-06-05 zacks
Akamai Technologies, Inc. (AKAM - Free Report) : This provider of cloud services has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 17.4% over the last 60 days.
AMOT ACRX AKAM

ACRX : AcelRx Pharmaceuticals Stock Analysis and Research Report

2017-10-30 - Asif

AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. Its lead product candidate, DSUVIA™ (known as ARX-04 outside of the United States), and its product candidate, ZALVISO®, utilize sublingual sufentanil, delivered via a non-invasive route of sublingual administration. The company anticipate developing a distribution capability and commercial organization to market and sell DSUVIA in the United States by itself, and potentially, in certain European Economic Area, or EEA, countries with strategic partners. In geographies where the company decide not to commercialize itself, the company may seek to out-license commercialization rights. The company intend to seek regulatory approval for ZALVISO in the United States and, if successful, potentially promote ZALVISO either by itself or with strategic partners. AcelRx Pharmaceuticals has chosen sufentanil as the therapeutic in...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ACRX / AcelRx Pharmaceuticals, Inc. on message board site Silicon Investor.

ACRX (MC $98M) Cash $72M/ FDA Decision Oct 12 (Blockbuster)
CUSIP: 00444T100